AI in drug discovery

News

Insilico Medicine and Servier logos on a black background

Insilico adds Servier to partnership roster with $888m deal

Insilico has added to its partnerships list with an $888m cancer-focused alliance with Servier, just days after completing its long-awaited IPO.

R&D

From complexity to cohesion: AI’s growing role in building s...

AI is being used from protocol design to study start-up and through clinical trial closeout, reshaping the trial lifecycle.

News

Insilico ends 2025 with $293m Hong Kong IPO

One of the pioneers in AI-powered drug discovery, Insilico Medicine, has completed an oversubscribed IPO in Hong Kong, raising around $293m.

Digital

pharmaphorum podcast Episode 231, Dr Alan Roth, Oxford Drug Design

On AI and computational support of biochemistry, with Alan R...

Dr Alan Roth, CEO of Oxford Drug Design, discusses the use of AI to accelerate discovery of new treatments.

News

Chai raises $130m for AI drug discovery platform

AI specialist Chai Discovery has said it is sitting on a valuation of around $1.3 billion, after raising $130 million in a Series B financing.

News

Lab-in-a-loop specialist Relation attracts Novartis alliance

UK-based AI and multi-omics company Relation Therapeutics will seek out targets for allergic diseases on behalf of Novartis in a $1.7bn-plus alliance.

Insilico adds Servier to partnership roster with $888m deal

From complexity to cohesion: AI’s growing role in building s...

Insilico ends 2025 with $293m Hong Kong IPO

On AI and computational support of biochemistry, with Alan R...

Chai raises $130m for AI drug discovery platform

Lab-in-a-loop specialist Relation attracts Novartis alliance

Allogeneic cell therapy isn’t dead, with Brian Culley

How to meet your physicians where they are online

AI in drug discovery

Editor's Picks